Exploring Biosimilars in the Field of Breast Cancer

Video

Jennifer Litton, MD, associate professor in the Department of Breast Medical Oncology at The University of Texas MD Anderson Cancer Center, discusses the role of biosimilars in the treatment of breast cancer.

Jennifer Litton, MD, associate professor in the Department of Breast Medical Oncology at The University of Texas MD Anderson Cancer Center, discusses the role of biosimilars in the treatment of breast cancer.

The cost of cancer treatments has become one of the biggest concerns to oncologists as they treat their patients, Litton says.

It is not ideal to send a patient into debt while they are being treated, and often times oncologists are making their decisions regarding treatment based off cost. Economic toxicity is a major issue in the field of breast cancer, as well as many other cancers, Litton notes.

Related Videos
Video 3 - "Managing Toxicities and Adverse Reactions in HR+/Her2-Low mBC Therapies"
Video 2 - "EMERALD: Underscoring Key Elacestrant Data + Subgroup Analyses for Informed Therapy Selection"
Video 1 - "A 62-Year-Old Woman with HR+ HER2-low Metastatic Breast Cancer and Lung, Liver, and Bone Metastases and Using Biomarker Testing to Guide Treatment Selection"
Related Content